Skip to main content

Market Overview

PerkinElmer: Q4 Earnings Insights


Shares of PerkinElmer (NYSE:PKI) moved higher by 0.1% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 193.33% over the past year to $3.96, which beat the estimate of $3.00.

Revenue of $1,355,000,000 higher by 68.22% year over year, which beat the estimate of $1,220,000,000.


PerkinElmer Sees Q1 Adj. EPS $3.00+ vs $2.40 Est., Sales $1.19B+ vs $1.1B Est.; Sees FY21 Adj. EPS $8.50+ vs $8.88 Est., Sales $4.08B+ vs $4.17B Est.

Conference Call Details

Date: Feb 02, 2021

Time: 05:00 PM

ET Webcast URL:


52-week high: $162.70

Company's 52-week low was at $62.91

Price action over last quarter: Up 18.10%

Company Overview

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes prenatal screening and infectious-disease testing, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening to environmental analytical tools.


Related Articles (PKI)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings